secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001701541-21-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing
------------------------------------------------------------------------------

- Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.
- R&D expenses $26.7M vs $10.2M in Q2 2020; net cash used in operations $49.6M.
- BDTX-189 Phase 1 data presented at ASCO; Phase 2 initiation on track for H2 2021 after FDA dialogue.
- IND filings planned: BDTX-1535 in H1 2022, BRAP and FGFR programs in 2022.
- Appointed Elizabeth Buck as CSO, Karsten Witt as interim CMO; Drs. Humphrey and Roberts departed; Mark Velleca added to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/0001701541-21-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/bdtx-20210812.htm
  HTML page:      https://secwatch.observer/filing/0001701541-21-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer